

Publications

Prof. Dr. Tom Stargardt

Peer-reviewed journal articles (accepted, online first & in print)

1. Achelrod D, Welte T, Schreyögg J, Stargardt T (2016): Costs and Outcomes of the German Disease Management Programme (DMP) for Chronic Obstructive Pulmonary Disease (COPD) - A large population-based cohort study, *Health Policy* (accepted & online first).
2. Fischer K, Heisser T, Stargardt T (2016): Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia, *Health Policy* (accepted & online first).
3. Hofer F, Achelrod D, Stargardt T (2016): Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany, *Applied Health Economics and Health Policy* (accepted & online first).
4. Blankart CB, Stargardt T (2016): Preferred supplier contracts in post-patent prescription drug markets, *Health Care Management Science* (accepted & online first).
5. Fischer K, Stargardt T (2016): The diffusion of generics after patent expiry in Germany, *European Journal of Health Economics* (accepted & online first).

Peer-reviewed journal articles

6. Frey S, Blankart CB, Stargardt T (2016): Economic burden and quality of life effects of chronic lymphocytic leukemia: A systematic review of the literature, *Pharmacoeconomics*. 34(5): 479-498.
7. Guhl D, Fischer K, Schneider U, Stargardt T (2016): Dispensing behaviour in pharmacy markets, *Health Policy*, 120(2):190-7.
8. Fischer K, Stargardt T (2014): Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions, *Medical Decision Making*, 34(8):1030-47.
9. Stargardt T, Schreyögg J, Kondofersky I (2014): Measuring the Relationship between Costs and Outcomes: the Example of Acute Myocardial Infarction in German Hospitals, *Health Economics*, 23(6):653-69.
10. Achelrod D, Blankart C, Linder R, Kodolitsch Y, Stargardt T (2014): The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study, *Orphanet Journal of Rare Diseases*; 9:90.

11. Achelrod D, Stargardt T (2014): Cost-Utility Analysis Comparing Heavy-Weight and Light-Weight Mesh in Laparoscopic Surgery for Unilateral Inguinal Hernias, *Applied Health Economics and Health Policy*, 12(2): 151-163.
12. Frey S, Linder R, Juckel G, Stargardt T (2014): Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia – a Markov model parameterized using administrative data from a German sickness fund, *European Journal of Health Economics*, 15(2):133-142.
13. Haas L, Stargardt T, Schreyoegg J, Schlösser R, Danzer G, Klapp B (2013): The trade-off between costs and quality of care in the treatment of psychosomatic patients with somatoform pain disorder, *Applied Health Economics and Health Policy*, 11(4):359-368.
14. Blankart R, Koch T, Linder R, Verheyen F, Schreyögg J, Stargardt T (2013): Cost of illness and economic burden of chronic lymphocytic leukemia, *Orphanet Journal of Rare Diseases*, 8(1):32.
15. Vondoros S, Stargardt T (2013): Reforms in the Greek pharmaceutical market during the financial crisis, *Health Policy*, 109(1):1-6.
16. Frey S, Stargardt T (2012): Compliance and persistence measurement using administrative data from German sickness funds, *Pharmacotherapy*, 32(10): 880-889.
17. Stargardt T, Schreyögg J (2012): A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data, *Health Policy*, 105(2-3): 110-118.
18. Roll K, Stargardt T, Schreyögg J (2012): Effect of type of insurance and income on waiting time for outpatient care, *Geneva Papers on Risk and Insurance - Issues and Practice*, 37(4): 609-632.
19. Stargardt T, Edel MA, Ebert A, Busse R, Juckel G, Gericke CA (2012): Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of schizophrenic patients in Germany, *Journal of Clinical Psychopharmacology*, 32(5): 602-607.
20. Haas L, Stargardt T, Schreyögg J (2012): Cost-effectiveness of open versus laparoscopic appendectomy in the US: a multilevel approach with propensity score matching, *European Journal of Health Economics*, 13(5): 549-60.
21. Bäuml M, Stargardt T, Schreyögg J, Busse R (2012): Cost-effectiveness of drug-eluting stents in AMI patients in Germany, *Applied Health Economics and Health Policy*, 10(4): 235-248.
22. Haas L, Stargardt T, Schreyögg J, Schlössel R, Danzer G, Klapp BF (2012): Introduction of DRG-based reimbursement in inpatient psychosomatics – An examination of cost homogeneity and cost predictors in the treatment of patients with eating disorders, *Journal of Psychosomatic Research*, 73(5): 383-90.
23. Schreyögg J, Stargardt T (2012): Gesundheitsökonomische Evaluation auf Grundlage von GKV-Routinedaten, *Bundesgesundheitsblatt*, 55: 668-676.

24. Haas L, Stargardt T, Schreyögg J, Schlösser R, Danzer G, Klapp BF (2012): Inpatient costs and predictors of costs in the psychosomatic treatment of anorexia nervosa, *International Journal of Eating Disorders*, 45(2): 214-21.
25. Stargardt T (2011): Modeling pharmaceutical prices in Germany as a function of competition and regulation, *Applied Economics*, 43(29): 4515-4526.
26. Schreyögg J, Stargardt T, Tiemann O (2011): Costs and quality of hospitals in different health care systems: a multi-level approach with propensity score matching, *Health Economics*, 20(1): 85-100.
27. Blankart R, Stargardt T, Schreyögg J (2011): Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and Chronic Myeloid Leukaemia, *Pharmacoeconomics*, 29(1): 63-82.
28. Roll K, Stargardt T, Schreyögg J (2011): Zulassung und Erstattung von Orphan Drugs im internationalen Vergleich, *Das Gesundheitswesen*; 73(8): 504-514.
29. Drummond M, Jönsson B, Rutten F, Stargardt T (2011): Obtaining value for money from pharmaceuticals: a comparison of reference pricing with health technology assessment, *European Journal of Health Economics*, 12(3):263-271.
30. Stargardt T, Mavrogiorgou P, Gericke CA, Juckel G (2011): Effectiveness and costs of flupentixol compared to other first and second generation antipsychotics in the treatment of schizophrenia, *Psychopharmacology*, 216(4): 579-87.
31. Schreyögg J, Stargardt T (2010): The Trade-Off Between Costs and Outcomes: The Case of Acute Myocardial Infarction, *Health Services Research*, 45(6):1585-601.
32. Stargardt T (2010): The Impact of Reference Pricing on Switching Behaviour and Healthcare Utilisation: The Case of Statins in Germany, *European Journal of Health Economics*, 11(3): 267-277.
33. Schreyögg J, Weller J, Stargardt T, Herrmann K, Dechow T, Glatting G, Krause BJ, Reske SN, Buck AK (2010): Cost-effectiveness of Hybrid PET/CT Imaging for Staging Non-Small Cell Lung Cancer, *The Journal of Nuclear Medicine*, 51 (11):1668-1675.
34. Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schwaiger M, Schreyögg J (2010): Economic Evaluation of PET and PET/CT in Oncology Evidence and Methodological Approaches, *The Journal of Nuclear Medicine*, 51(3):401-412.
35. Stargardt T, Gonder-Frederick L, Krobot K, Alexander C (2009): Fear of Hypoglycaemia: Defining a Minimum Clinically Important Difference, in *Health and Quality of Life Outcomes*, 7(91).
36. Marett L, Stargardt T, Mavros P, Alexander C (2009): Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain, in *Diabetes Obesity and Metabolism*, 11: 1138-1144.

37. Stargardt T, Alexander C, Yin D (2009): Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus, *Diabetes Obesity and Metabolism*, 11: 491-497.
38. Weinbrenner S, Assion H, Stargardt T, Busse R, Juckel G, Gericke C (2009): Antipsychotic prescription patterns for schizophrenic outpatients in Germany, *Pharmacopsychiatry*, 42(2): 66-71.
39. Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke C (2008): Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care: retrospective cohort study, *Journal of Mental Health Policy and Economics*, 10(2): 89-97.
40. Stargardt T (2008): Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries, *Health Economics*, 17(S1): 9-20.
41. Schreyögg J, Tiemann O, Stargardt T, Busse R (2008): Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories, *Health Economics*, 17(S1): 95-103.
42. Stargardt T, Schreyögg J, Busse R (2007): Pricing Behaviour of Pharmacies After Market Deregulation for OTC Drugs: The Case of Germany, *Health Policy*, 84(1): 30-38.
43. Stargardt T, Schreyögg J (2006): The Impact of Cross-reference Pricing on Pharmaceutical Prices – Manufacturers' Pricing Strategies and Price Regulation, *Applied Health Economics and Health Policy*, 5(4): 235-247.
44. Schreyögg J, Stargardt T, Tiemann O, Busse R (2006): Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries, in: *Health Care Management Science*, 9(3):215-224.
45. Velasco-Garrido M, Schreyögg J, Stargardt T, Busse R (2006): Description des paniers de soins de neuf pays de l'Union européenne, in: *Revue française des Affaires sociales*, 2-3:32-90.
46. Stargardt T, Schreyögg J, Busse R (2005): Arzneimittelfestbeträge: Gruppenbildung, Preisberechnung mittels Regressionsverfahren und Wirkungen, in: *Das Gesundheitswesen*, 67(7):469-478.
47. Schreyögg J, Stargardt T, Velasco-Garrido M, Busse R (2005): Defining the benefit basket in nine European countries: Evidence from EU-HealthBASKET project, in: *European Journal of Health Economics*, 6(S1):2-10.
48. Busse R, Stargardt T, Schreyögg J (2005): Determining the benefit basket of the Statutory Health Insurance scheme in Germany: methodologies and criteria, in: *European Journal of Health Economics*, 6(S1):30-36.
49. Farhauer O, Borchardt K, Stargardt T (2004): Bürgerversicherung – Die Wirkung von Kopfprämien auf den Arbeitsmarkt, in: *Zeitschrift für die gesamte Versicherungswissenschaft*, 93(3):349-372.

Non peer-reviewed publications

a) Books and book chapters

1. Stargardt T, Vondoros S (2014): Pharmaceutical Pricing and Reimbursement Regulation in Europe, in: Culyer JA [ed.], Encyclopedia of Health Economics, Vol 3. San Diego: Elsevier, 29-36.
2. Blankart R, Roll K, Heimeshoff M, Stargardt T, Schreyögg J (2014): Innovationsbedarf in der Gesundheitswirtschaft im Spiegel der Forschung, in: Bieber D, Geiger M [Hrsg.]: Personenbezogene Dienstleistungen im Kontext komplexer Wertschöpfung, Springer, pp. 257-267.
3. Busse R, Schreyögg J, Stargardt T [Hrsg.] (2012): Management im Gesundheitswesen, Springer.
4. Stargardt T, Schreyögg J (2012): Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Stargardt T: Management im Gesundheitswesen, Springer, pp. 128-148.
5. Stargardt T, Tiemann O (2012): Personalmanagement im Gesundheitswesen – Einführung und methodische Grundlagen, in: Busse R, Schreyögg J, Stargardt T: Management im Gesundheitswesen, Springer, pp. 336-338.
6. Schreyögg J, Stargardt T (2009): Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Gericke C: Management im Gesundheitswesen, Springer, S. 122-140.
7. Schreyögg J, Stargardt T (2006): Leistungsmanagement in der Arzneimittelindustrie, in: Busse R, Schreyögg J, Gericke C: Management im Gesundheitswesen, Springer, S. 123-141.

b) Other publications

1. Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bänsch S, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC (2016): Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern, Herzschrittmachertherapie+ Elektrophysiologie, 1-12.
2. Vondoros S, Stargardt T (2013): Authors' response to 'Health service expenditures and efficiencies in Greece', Health Policy, 111(2): 208-209.
3. Schreyögg J, Schultz C, Stargardt T, Busse R (2012): Focus on designing health care structures and services for rare diseases, Health Policy, 105(2-3): 107-109.
4. Roll K, Stargardt T, Schreyögg J (2012): Einfluss von Versichertenstatus und Einkommen auf die Wartezeit im ambulanten Bereich, Monitor Versorgungsforschung, 5(5): 27-29.
5. Stargardt T (2006) Focus on Germany, Reference Pricing, in: Pharmaceutical Marketing Europe, 3(1):32-34.

6. Farhauer O, Borchardt K, Stargardt T (2005): Bürgerversicherung * Systematisierung und Bewertung der Reformvarianten, in: Wirtschaftswissenschaftliches Studium WiSt, 34(6):308-314.